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AbstrACt
Introduction Lung cancer is a leading cause of cancer 
deaths worldwide and surgery remains the main treatment 
for early stage disease. Prior to the introduction of video-
assisted thoracoscopic surgery (VATS), lung resection for 
cancer was undertaken through an open thoracotomy. To 
date, the evidence base supporting the different surgical 
approaches is based on non-randomised studies, small 
randomised trials and is focused mainly on short-term 
in-hospital outcomes.
Methods and analysis The VIdeo assisted thoracoscopic 
lobectomy versus conventional Open LobEcTomy for lung 
cancer study is a UK multicentre parallel group randomised 
controlled trial (RCT) with blinding of outcome assessors 
and participants (to hospital discharge) comparing the 
effectiveness, cost-effectiveness and acceptability of VATS 
lobectomy versus open lobectomy for treatment of lung 
cancer. We will test the hypothesis that VATS lobectomy 
is superior to open lobectomy with respect to self-
reported physical function 5 weeks after randomisation 
(approximately 1 month after surgery). Secondary 
outcomes include assessment of efficacy (hospital stay, 
pain, proportion and time to uptake of chemotherapy), 
measures of safety (adverse health events), oncological 
outcomes (proportion of patients upstaged to pathologic 
N2 (pN2) disease and disease-free survival), overall 
survival and health related quality of life to 1 year. The 
QuinteT Recruitment Intervention is integrated into the trial 
to optimise recruitment.
Ethics and dissemination This trial has been approved 
by the UK (Dulwich) National Research Ethics Service 
Committee London. Findings will be written-up as 
methodology papers for conference presentation, and 
publication in peer-reviewed journals. Many aspects of 
the feasibility work will inform surgical RCTs in general 
and these will be reported at methodology meetings. We 
will also link with lung cancer clinical studies groups. The 
patient and public involvement group that works with the 
Respiratory Biomedical Research Unit at the Brompton 
Hospital will help identify how we can best publicise the 
findings.
trial registration number ISRCTN13472721
IntroduCtIon
background and objectives
Lung cancer is a leading cause of cancer 
death worldwide and survival in the UK 
remains among the lowest in Europe. 
Surgery, conventionally undertaken through 
an open thoracotomy for lung resection, 
remains the treatment for early stage disease. 
The randomised trial comparing lobectomy 
with limited resection (segment or wedge), 
published in 1995 concluded that lobectomy 
should be the surgical procedure for patients 
with lung cancer.1 The only grade 1 evidence 
published since is a post-hoc analysis of the 
CALGB/Alliance 140 503 trial in patients with 
strengths and limitations of this study
 ► First multicentre randomised trial on this topic.
 ► All surgeons carry out both interventions; the rando-
misation scheme ensures surgeon balance across 
the groups to minimise performance bias.
 ► Masking of the incision and evaluation of the suc-
cess of blinding.
 ► Procedures reflective of UK practice (majority are 
postero-lateral thoracotomy).
 ► Surgeon crossovers (ie, surgeon changes after ran-
domisation) can occur in centres with pooled service 
provision.
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Figure 1 The trial schema showing the recruitment pathway 
for phase 1 (pilot phase) of the VIOLET study. VATS, video-
assisted thoracoscopic surgery; VIOLET, VIdeo assisted 
thoracoscopic lobectomy versus conventional Open 
LobEcTomy for lung cancer.
Figure 2 The trial schema showing the recruitment pathway 
for phase 2 of the VIOLET study. VATS, video-assisted 
thoracoscopic surgery; VIOLET, VIdeo assisted thoracoscopic 
lobectomy versus conventional Open LobEcTomy for lung 
cancer.
peripheral non-small-cell lung cancer, which concluded 
that lobar and sublobar resection had similar periopera-
tive mortality and morbidity outcomes.2 Since the intro-
duction of minimal access video-assisted thoracoscopic 
surgery (VATS) techniques, lung cancer resection under-
taken through a VATS approach increased from 14% in 
2010 to 40% in 2014 in the UK.3
Much of the evidence generated to date is based on 
non-randomised studies4 5 or small randomised trials 
focusing on short-term (in-hospital) outcomes,6 that 
are underpowered to detect differences in longer 
term outcomes such as survival7 or have focused solely 
on operative technique.8 Currently, the most well-de-
signed randomised controlled trial (RCT) by Bendixen 
et al, reported shorter hospital stay and less pain in 
patients randomised to VATS lobectomy.9 In this study, 
all patients received epidural anaesthesia and ante-
rior thoracotomy for open surgery which is not the 
current practice for most thoracic surgery centres in 
the UK. In contrast, a recent trial by Hao et al from 
China, published in 2018, reported a similar hospital 
stay in the VATS and axillary thoracotomy groups.10 In 
addition, little high quality randomised data has been 
published to ascertain the cost effectiveness (ie, quality 
of life and costs) for VATS, highlighted in a follow-up 
report by Bendixen et al and an on-going trial in France 
(Lungsco1) that will specifically compare VATS lobec-
tomy versus open thoracotomy from an economic cost 
to society perspective.11 12
A well designed and conducted RCT comparing the 
effectiveness and cost-effectiveness of minimal access and 
open surgery is needed to inform current UK (National 
Health Service; NHS) practice, health policy and indi-
vidual surgeon and patient decision-making.
The VIdeo assisted thoracoscopic lobectomy versus 
conventional Open LobEcTomy for lung cancer 
(VIOLET) study is a UK multicentre pragmatic RCT 
comparing the effectiveness, cost-effectiveness and 
acceptability of VATS lobectomy versus open lobectomy 
for treatment of lung cancer.
Aims and objectives
The VIOLET study will test the hypothesis that VATS 
lobectomy is superior to open lobectomy with respect to 
self-reported physical function 5 weeks after randomisa-
tion (approximately 1 month after surgery).
Specific objectives are to estimate:
1. The difference between groups in the average self-re-
ported physical function at 5 weeks.
2. The difference between groups with respect to a range 
of secondary outcomes including assessment of effica-
cy (hospital stay, pain, proportion and time to uptake 
of chemotherapy), measures of safety (adverse health 
events), oncological outcomes (proportion of patients 
upstaged to pN2 disease and disease-free survival) and 
overall survival.
3. The cost-effectiveness of VATS lobectomy compared 
with open lobectomy.
MEthods
trial design
A UK-based multicentre parallel group RCT with 
blinding of outcome assessors and participants until 
hospital discharge after surgery. Figures 1 and 2 show the 
expected patient pathway for both phases of recruitment 
to the VIOLET study.
Phase 1: The first phase with an integrated qualitative 
component is necessary to establish the processes for 
recruitment and consent. This phase is also essential to 
develop a study manual and a measure of surgical exper-
tise to proceed to phase 2. Phase 1 will be conducted in 
five centres; Royal Brompton Hospital in London, The 
University Hospitals Bristol in Bristol, Liverpool Heart 
and Chest Hospital in Liverpool, The James Cook Univer-
sity Hospital in Middlesbrough and Harefield Hospital in 
Harefield. These centres are well spread geographically 
and represent a mix of university and NHS trusts that are 
representative of NHS practice. Progression from pilot to 
the full trial will be dependent on preagreed progression 
criteria (assessed after 18 months of recruitment):
Specifically:
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a. At least 60% of patients undergoing lobectomy are 
considered eligible for the trial (if necessary, by revis-
ing the eligibility criteria).
b. At least 50% consent to randomisation after 6 months 
of recruitment.
c. Less than 5% fail to receive their allocated treatment.
d. Less than 5% lost to follow-up, excluding deaths.
Phase 2: This phase will extend the study to up to a 
further five centres. All centres will use the optimum 
methods of recruitment established in phase 1 and will 
follow-up all participants to 1 year.
study population
Participating centres will only be eligible if they meet all 
the following eligibility criteria: (1) NHS Trust with an 
established and accredited lung cancer multi-disciplinary 
team (MDT). (2) Centre carries out ≥40 VATS lobecto-
mies each year and employs at least one surgeon who has 
carried out ≥50 VATS lobectomies.
Participating surgeons will be eligible for the trial if 
they have performed ≥50 VATS lobectomies. Prospective 
surgeons will be required to submit their activity logs, 
which will be validated against local audit data from the 
MDT meetings, prior to acceptance to the trial. Lobec-
tomy via open surgery is currently standard procedure 
and therefore surgical ability and competence will be 
assured by specialist UK General Medical Council (GMC) 
registration.
Patients may enter the study if all the following apply:
1. Adult aged ≥16 years of age.
2. Able to give written informed consent, undergoing ei-
ther: (a) lobectomy or bilobectomy for treatment of 
known or suspected primary lung cancer beyond lobar 
orifice* in tumour, node, metastases TNM8 stage cT1-
3 (by size criteria, equivalent to TNM7 stage cT1a-2b) 
or cT3 (by virtue of 2 nodules in the same lobe), N0-1 
and M0 or (b) undergoing frozen section biopsy with 
the intention to proceed with lobectomy or bilobecto-
my if primary lung cancer with a peripheral tumour 
beyond a lobar orifice* in TNM8 stage cT1-3 (by size 
criteria, equivalent to TNM7 stage cT1a-2b) or cT3 (by 
virtue of 2 nodules in the same lobe), N0-1 and M0 is 
confirmed.
3. Disease suitable for both minimal access (VATS lobec-
tomy) and lobectomy via open surgery.
*In the case of bilobectomy, the distance for the ‘lobar’ 
orifice is in reference to the bronchus intermedius.
Patients may not enter the study if any of the following 
apply:
1. Previous malignancy that influences life expectancy.
2. Pneumonectomy, segmentectomy or non-anatomic re-
section (eg, wedge resection) is planned.
3. Patient has a serious concomitant disorder that would 
compromise patient safety during surgery.
4. Planned robotic surgery.
randomisation
Participants will be randomised in a 1:1 ratio to either 
VATS lobectomy or open lobectomy. Randomisation will 
take place through a secure internet-based randomisation 
system, access to which will be restricted to authorised 
study personnel. Cohort minimisation (with a random 
element incorporated) will be used to ensure balance 
across groups with respect to the surgeon and the alloca-
tion will be stratified by centre.
Due to the pragmatic nature of this trial there will inev-
itably be some variability between surgeons, the surgical 
teams and the perioperative processes. Such heteroge-
neity is important as this accurately reflects real clinical 
practice.
Randomisation will be performed 1 week prior to 
the planned operation date, once eligibility has been 
confirmed and written consent taken by a research nurse. 
This will allow sufficient time for operating theatre sched-
ules to be arranged. If there is a change in surgeon after 
randomisation, the analysis will account for the surgeon 
responsible for performing the operation and not the 
surgeon originally allocated to the patient.
trial interventions
All operations will be undertaken with general anaesthesia 
and with the patient in the lateral decubitus position.
VATS lobectomy is undertaken through one to four 
keyhole incisions without rib spreading. The use of ‘rib 
spreading’ is prohibited as this is the key intra-operative 
manoeuvre which disrupts tissues and causes pain (and 
is used in open surgery). The procedure is performed 
with videoscopic visualisation without direct vision. The 
hilar structures are dissected, stapled and divided. Endo-
scopic ligation of pulmonary arterial branches may be 
performed. The fissure is completed and the lobe of 
lung resected. The incisions are closed in layers and may 
involve muscle, fat and skin layers. This definition of VATS 
lobectomy is a modification of Cancer and Leukaemia 
Group B (CALGB) 39 802.13
Conventional open lobectomy is undertaken through 
a single incision with or without rib resection and with 
rib spreading. The operation is performed under direct 
vision with isolation of the hilar structures (vein, artery 
and bronchus) which are dissected, ligated and divided 
in sequence and the lobe of lung resected. The proce-
dures may be undertaken using ligatures, over sewing or 
with staplers. The thoracotomy is closed in layers starting 
from pericostal sutures over the ribs, muscle, fat and skin 
layers.
In both groups, lymph node management is under-
taken in accordance with the International Association 
of the Study of Lung Cancer recommendations where a 
minimum of six nodes/stations are removed, of which 
three are from the mediastinum that includes the subca-
rinal station.14
Because this is a pragmatic trial, adaptations and vari-
ation in both procedures (with the exception of the 
mandated elements outlined above) will be permitted 
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Table 1 Data collection for trial participants who agree to randomisation to VATS lobectomy or open lobectomy
Pre-randomisation Post-randomisation
Baseline
Day of 
surgery Postop
2 days 
postop Discharge
2 
weeks*
5 
weeks*
3 
months*
6 
months* 1 year*
Eligibility X
Imaging review (CT/
Positron Emmission 
Tomography (PET)--
CT†)
X
Participant 
characteristics
X
Audio recorded 
consultation
X
Lobectomy via VATS 
lobectomy or open 
lobectomy
  X
Intraoperative details   X
Histopathology staging   X
Tumour sample for 
research
  X
Patient questionnaires
  QLQ-C30 X X X X X X
  QLQ-LC13 X X X X X X
  EQ5D X X X X X X
  Bang Blinding Index   X X
Pain score X X X
Adverse events   X X X X X
Resource use X X X X X X
CT scan of chest and 
abdomen
  X
*Follow-up time-points will be calculated from the date of randomisation.
†Review of images available from staging scans performed in accordance with standard practice at participating centres.
QLQ, Quality of Life Questionnaire; VATS, video-assisted thoracoscopic surgery.
although intraoperative details will be collected, and 
compliance monitored.
Primary and secondary outcomes
The primary outcome is self-reported physical function 
measured using the European Organization for Research 
and Treatment of Cancer Quality of Life Question-
naire-C30 (EORTC QLQ-C30) at 5 weeks post-randomi-
sation. Physical function has been chosen because it is a 
patient-centred outcome that will reflect the anticipated 
earlier recovery with VATS lobectomy and has been used in 
other minimal access surgery trials. The primary endpoint 
has been chosen to be 5 weeks (1 month post-surgery) to 
capture the early benefits of minimal access surgery on 
recovery. The EORTC QLQ-C30 has been validated for 
use in European cohorts. In addition to assessing phys-
ical function the questionnaire also assesses psychological 
and social well-being. Secondary outcomes have been 
selected to assess the efficacy of the two approaches.
Secondary outcomes are (1) time from surgery to 
hospital discharge; (2) adverse health events; (3) propor-
tion and time to uptake of adjuvant treatment; (4) 
proportion of patients upstaged to pN2 disease after the 
procedure; (5) overall and disease-free survival to 1 year; 
(6) proportion of patients who undergo complete resec-
tion during the procedure; (7) proportion of patients 
who experience prolonged incision pain defined as the 
need for analgesia >6 weeks after surgery; (8) generic and 
disease-specific health-related quality of life (HRQoL) 
assessed using the EORTC QLQ-C30, QLQ-LC13 and 
EQ-5D-5L questionnaires completed at 2 weeks, 5 weeks, 
3 months, 6 months and 1 year post-randomisation); (9) 
resource use measured for the duration of post-operative 
hospital stay until discharge and at 5 weeks, 3 months, 6 
months and 1 year post-randomisation.
data collection
The schedule of data collection for the study is shown in 
table 1. Data will be collected on paper and then entered 
onto a bespoke database. Access to the database will be via 
a secure password-protected web-interface (NHS clinical 
portal). Study data transferred electronically between the 
University of Bristol and the NHS will only be transferred 
via a secure  NHS. net network in an encrypted form.
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blinding of staff and study participants
The operating surgeon and staff responsible for the care 
of the participant during the operation cannot be blinded 
to the participants’ treatment allocation. However, in 
order to minimise the risk of bias, attempts will be made 
to blind the research nurse responsible for the collec-
tion of follow-up data. Specifically, randomisation will 
be performed by a member of the research team who is 
not responsible for the collection of follow-up data for 
VIOLET study participants.
Furthermore, efforts will be made to minimise the risk 
of inadvertent unblinding of the research nurse respon-
sible for data collection during the patient’s postoperative 
stay. To accomplish this, large adhesive dressings will be 
applied to thorax. These adhesive dressings will be posi-
tioned similarly for all participants, regardless of their 
surgical allocation and will cover both real and potential 
incision/port locations. The initial adhesive dressings will 
be applied in the operating theatre by the operating team 
and these will not be changed until 3 days after surgery 
(or discharge if discharged before day 3), unless soiling 
or lack of adherence prompts their premature replace-
ment. Three days after surgery, dressings will be changed 
by a nurse who is not responsible for conducting the 
participants’ follow-up assessments. Wound cleaning will 
be performed on all real and potential incision/port loca-
tions to promote allocation masking.
Patients who agree to participate in the RCT will not 
be informed of their treatment allocation until they are 
discharged from hospital after their operation. In order 
to ensure that study patients are not unblinded during 
wound cleaning and dressing change, participants will be 
asked to turn their head away from the wound site that 
is being tended to. When participants are considered 
‘fit-for-discharge’, they will be informed of their treatment 
allocation and advised as to how best to care for their 
surgical wounds. Blinding in surgical trials are consid-
ered challenging yet an important aspect to reduce bias, 
patient drop-out and increase the validity of results.15–17 
Participants are made aware at consent that they will not 
be informed of their treatment allocation until after their 
surgery. Blinding was approved by the research ethics 
committee.
The success of blinding will be monitored during each 
participant’s in-hospital stay. Participants will be asked to 
complete the Bang-blinding Index18 at 2 days postopera-
tively and at discharge, but before the treatment alloca-
tion is revealed. The research nurse responsible for data 
collection and follow-up of VIOLET study participants 
will also be asked to complete the Bang-blinding Index 
when the participant is ready for discharge and after the 
participant attends for their 5-week and 1-year follow-up 
appointments.
standardisation of postoperative management
As this is a pragmatic RCT, postoperative care and the 
criteria for drain removal will be in accordance with 
local practice. However, we have identified two elements 
of patient care, which require standardisation to mini-
mise the potential for bias, namely pain-control and the 
criteria by which a participant’s medical fitness-for-dis-
charge is assessed.
Standardising the use of analgesia across participating 
centres is impractical and does not reflect the intended 
pragmatic nature of the trial, it, would also produce data 
unrepresentative of real clinical practice. Therefore, each 
participating centre will prescribe analgesia in accor-
dance with their local protocols. All patients recruited to 
the RCT at that centre will be given the same analgesia 
regardless of their treatment allocation (ie, VATS lobec-
tomy or open lobectomy). Local protocols for the provi-
sion of analgesia will be defined by the local Principal 
Investigator (in collaboration with the local research 
team) prior to the start of recruitment to the RCT. 
Analgesia administered throughout the participant’s 
in-hospital stay will be recorded on the trial case report 
forms (CRFs) and compliance with the predefined and 
centre-specific analgesia protocols will be monitored.
In order to objectively compare the time from surgery 
to hospital discharge between VATS lobectomy and open 
lobectomy, the following discharge suitability criteria 
have been developed. Study participants will be evaluated 
against these criteria to ensure that they are medically 
fit-for-discharge:
 ► Participant has achieved satisfactory mobility.
 ► Pain under control with analgesia.
 ► Satisfactory serum haemoglobin and electrolytes (ie, 
does not require intervention).
 ► Satisfactory chest X-ray (which will be performed as 
part of routine clinical care).
 ► No complications that require further/additional 
treatment.
Participants who are considered medically fit-for-dis-
charge may not necessarily be discharged immediately; 
in some instances, social and other factors may necessi-
tate extended hospitalisation. The time at which partici-
pants are considered medically fit-for-discharge and when 
they are physically discharged from hospital will both be 
recorded on the trial CRFs.
sample size calculation
We hypothesise that self-reported physical function (scale 
0–100, with higher scores indicating better function) 
5 weeks after randomisation for participants undergoing a 
VATS lobectomy will be superior to the physical function 
for participants having an open lobectomy, as measured 
using the EORTC QLQ-C30. The sample size has been 
chosen to test this hypothesis.
Although the primary endpoint is at 5 weeks post-ran-
domisation self-reported physical function will also be 
assessed at other time points (baseline, 2 weeks, 3 months, 
6 months and 1 year). In estimating the sample size these 
additional measurements have been taken into account. 
The power calculation requires the estimation of four 
parameters (ie, the effect size that would be considered 
clinically important, the number of pre-surgery and 
by copyright.
 o
n
 January 16, 2020 at University of Bristol Library. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029507 on 14 October 2019. Downloaded from 
6 Lim E, et al. BMJ Open 2019;9:e029507. doi:10.1136/bmjopen-2019-029507
Open access 
post-surgery measures, and the correlations between 
pre-surgery and post-surgery scores and between repeated 
post-surgery scores). The effect size was chosen based on 
the published literature,19 which suggests that an effect 
size of 0.2 to 0.6 SD equates to a clinically important 
difference in physical function score of between 5 and 
14 points or approximately a one category change in 
performance status. In the absence of data from which 
to estimate the correlations between repeated measures, 
we assumed conservative estimates (0.3 between pre and 
post measures, 0.6 between repeated post measures).
The study size has been set at 398; allowing for a 20% 
dropout at 1 year, the target sample size is 498 partici-
pants. This will provide 90% power to test the hypothesis, 
assuming an effect size of 0.25 SD in physical function 
would be clinically important. The calculation based on 
five postsurgery measures assumes the treatment differ-
ence is similar at the five time points.
However, it is anticipated that the difference in physical 
function may change over time. The calculation based 
on a single measure shows that the study will have >80% 
power to detect a difference of 0.25 SD and >90% power 
to detect a difference of 0.3 SD at the primary endpoint 
where dropout is expected to be less than 5%.
A study in 498 participants will also have 80% power 
to detect a 1 day difference in length of hospital stay (ie, 
median 3 days vs 4 days, HR 1.3); assuming 2% of patients 
do not survive to discharge.
research procedures
Generic and disease-specific HRQoL measures will assess 
the profiles of VATS and open lobectomy in the early 
and mid-postoperative phases. The extensively validated 
EQ-5D-5L will assess generic aspects of HRQoL and will 
be used in the economic evaluation.20 21 The EORTC 
QLQ-C30 is one of the most widely used instruments 
for assessing HRQoL in patients with cancer and the 
QLQ-LC13 is the lung cancer module with 13 items that 
assesses lung cancer–specific symptoms.
Study participants will be asked to complete HRQoL 
questionnaires at baseline and postoperatively at 2 weeks, 
5 weeks, 3 months, 6 months and 1 year post-randomis-
ation. Baseline questionnaires will be administered by 
the research team at site, whereas the questionnaires 
completed post-operatively will be administered by the 
coordinating centre. Participants can choose to receive 
post-operative questionnaires by post or complete via a 
secure website.
Patient and public involvement
The Royal Brompton Hospital Cancer Consortia patient 
and public involvement (PPI) group were involved 
from inception and advised on trial design, identifica-
tion of the choice and timing of the primary outcome, 
and secondary outcomes that were considered to be 
important. They were consulted between August 2012 
and September 2013. The aim of PPI involvement in 
VIOLET was to advise on patient-orientated outcomes 
that matter. The group consists of four patients who have 
undergone surgery for cancer and one carer. Dr Hall, 
who is a patient, and a general practitioner by profession, 
has agreed to sit on the trial steering committee (TSC).
The PPI group will also be involved in reviewing the 
content and format of PILs and dissemination of the 
results of the study.
Integrated Quintet recruitment Intervention
The VIOLET study will employ an integrated QuinteT 
Recruitment Intervention (QRI) to optimise and sustain 
recruitment throughout the recruitment period because 
recruitment is anticipated to be difficult. Although 
recruitment to RCTs is recognised as a research priority,22 
there is a dearth of robust evidence about effective strate-
gies to improve recruitment in RCTs.23 Surgical RCTs face 
specific recruitment challenges due to the complex nature 
of surgical procedures, the dependence on many health-
care professionals across disciplines and surgeon-related 
factors such as variations in individual practice/exper-
tise.24 In addition, surgical RCTs, such as VIOLET, that 
compare minimally invasive and open operations have 
historically been difficult to conduct and recruit to.25 26
The QRI, employing primarily qualitative research 
methods can be used to understand recruitment in 
specific RCTs27–29 as well as across RCTs.30–32 It has been 
shown to optimise recruitment and informed consent, 
thereby contributing to successful recruitment and trial 
completion.33–35 In VIOLET, in order to understand the 
recruitment process at each centre in real time, investi-
gate the sources of recruitment difficulties and address 
the challenges, some of the key methods employed36 will 
be as follows:
Patient pathway through eligibility and recruitment: A 
comprehensive process of logging potential trial patients 
through screening and eligibility phases will be under-
taken to provide basic data about the levels of eligibility 
and recruitment, and identify points at which patients opt 
in or out of the RCT.
In-depth interviews: In-depth, semi-structured interviews 
will be conducted and audio-recorded with a purposive 
sample of staff members involved with aspects of trial 
design/management and recruitment across centres in 
phase 1 (and phase 2 where necessary). Patients eligible 
for recruitment to the RCT may also be interviewed. 
Across the different groups, interviews will explore partic-
ipants’ perspectives of the trial, the two procedures and 
acceptability of randomisation between procedures. In 
addition, recruitment staff (primarily surgeons) inter-
views will explore their experiences of undertaking both 
procedures (where appropriate), perceptions of equi-
poise for themselves and their colleagues, and views on 
likely outcome of the trial. Interview topic guides will 
be used to ensure similar topic areas are covered across 
interviews, while still providing the scope for participants 
to raise issues of pertinence to them.
Audio recording of recruitment appointments: Face-to-face 
and telephone consultations of healthcare staff (thoracic 
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surgeons, nurses etc) with potentially eligible patients 
will be routinely audio recorded across centres to under-
stand the recruitment process at each centre and to iden-
tify and investigate the challenges to recruitment. The 
QRI researcher will listen to and qualitatively analyse the 
appointments, documenting instances such as unclear, 
insufficient or imbalanced information provision and 
unintentional transferring of clinician treatment prefer-
ences to patients.
An account of the anonymised findings from all the 
data will be fed back to the RCT chief investigator (CI), 
with a plan of action to optimise recruitment developed 
collaboratively with key stakeholders. The data will be 
used by the QRI team to provide supportive and confi-
dential individual and group feedback to recruiters to 
help them to communicate equipoise, balance treatment 
options and explain to patients the benefits and purposes 
of trial participation, while optimising informed consent. 
Feedback sessions will include comparisons between what 
clinicians think they say to patients (interview data) and 
what they actually say to patients (consultation data). 
Rates of recruitment of eligible patients will be closely 
monitored against the feedback meetings, and it is 
expected that an improvement will be demonstrated in 
recruitment over time with experience and training for 
recruiters. (As we have demonstrated is possible in other 
similar trials.27–29 33–35)
Economic evaluation
The economic evaluation will compare the costs and 
effects of VATS lobectomy versus open lobectomy, 
and will follow established guidelines as set out by the 
National Institute for Health and Care Excellence.37 The 
within-trial cost-effectiveness analysis will be undertaken 
from an NHS and personal social services perspective, 
with a 1 year time horizon from the day of surgery. The 
primary outcome measure for the economic evaluation 
will be quality-adjusted life-years (QALYs), estimated 
using the EuroQol EQ-5D-5L, administered at baseline 
(pre-randomisation) and five time points post-randomi-
sation (see table 1). Resource use data collection will be 
integrated into the trial CRFs for the index admission 
for items such as duration of surgery, number of staples 
used and length of stay; and captured from participants 
regularly during the 1-year follow-up (see table 1) for 
events such as hospital readmissions, outpatient atten-
dances and general practitioner (GP) or nurse visits in 
the community.
statistical analysis plan
The data will be analysed on intention to treat (ITT) 
and follow Consolidated Standards of Reporting Trials 
reporting guidelines (http://www. consort- statement. 
org/). Randomised participants who are not found to 
have lung cancer will be included in the primary anal-
ysis, but a modified ITT analysis excluding these partic-
ipants will also be performed. Analyses will be adjusted 
for centre and for design factors included in the cohort 
minimisation (eg, the operating surgeon). As the alloca-
tion to VATS or open lobectomy is minimised by surgeon, 
clustering may occur within the dataset. The structure 
of the data, that is, nesting of patients by surgeon and 
centre, will be accounted for in the primary analysis.
Patient-reported outcome scores (HRQoL) and will be 
compared using a mixed regression model, adjusted for 
baseline measures where appropriate. Changes in treat-
ment effect with time will be assessed by adding a treat-
ment × time interaction to the model and comparing 
models using a likelihood ratio test. Deaths will be 
accounted for by modelling HRQoL and survival jointly. 
Model fit will be assessed and alternative models and/
or transformations (eg, to induce normality) will be 
explored where appropriate.
Missing items or errors on questionnaire measures will 
be dealt with according to the scoring manuals or via 
imputation methods. For other outcomes a complete case 
analysis will be undertaken if fewer than 5% of cases have 
missing data, otherwise multiple imputation methods 
will be considered. Compliance rates will be reported, 
including the numbers of patients who have withdrawn 
from the study, have been lost to follow-up or died. Causes 
of death for trial participants will be recorded.
Frequencies of adverse events will be described. Treat-
ment differences will be reported with 95% CIs. In this 
study of 498 patients, we are underpowered to detect 
differences in survival of less than approximately 20% 
at 2 years. However, survival rates and 95% CIs will be 
reported.
One subgroup analysis is planned, comparing pain 
scores by type of analgesia (paravertebral block vs inter-
costal block). This will be tested by adding an analgesia by 
treatment interaction term to the model. In addition, as 
an exploratory analysis we will report pain scores within 
the VATS lobectomy group by number of port sites (single 
vs multiple port sites), but a formal comparison between 
the sub-sets of the VATS group is not planned.
The primary analysis will take place when follow-up is 
complete for all recruited participants. Interim analysis 
will be decided in discussion with the Data Monitoring 
and Safety Committee. There is no intention to compare 
any outcomes between groups after phase 1; the only 
analyses will be descriptive statistics to summarise recruit-
ment to decide whether the trial satisfies the progression 
criteria.
Economic Evaluation: For the economic evaluation, unit 
costs will be derived from nationally published sources 
and attached to resource use data, and the total costs per 
participant calculated. Responses to the EQ-5D-5L will be 
assigned valuations derived from published UK popula-
tion tariffs,38–40 and combined with survival to calculate 
QALYs gained per participant. Missing resource use and 
EQ-5D-5L data will be handled using multiple imputation 
methods.41 From the average costs and QALYs gained 
in each trial group, the incremental cost-effectiveness 
ratio will be derived, producing an incremental cost per 
QALY gained of VATS lobectomy compared with open 
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lobectomy. Univariate and multivariate sensitivity anal-
yses will assess the impact of varying key parameters in the 
analysis on baseline cost-effectiveness results. Results will 
be expressed in terms of a cost-effectiveness acceptability 
curve, which indicates the likelihood that VATS lobec-
tomy is cost-effective for different levels of willingness to 
pay for health gain.
Qualitative analysis: Analysis of qualitative data will 
involve transcribing the audio-recorded consultations, 
interviews and meetings with consent. The QRI researcher 
will (a) analyse the transcripts and notes thematically 
using techniques of constant comparison42 and case study 
approaches to explore the ‘clear obstacles’ and ‘hidden 
challenges30 to recruitment in VIOLET, and (b) employ 
targeted conversation analysis27 to focus on areas in the 
consultations where communication appears to struggle 
or break down to identify aspects of recruitment that 
could be improved. Subsets of interview and consultation 
transcripts will be independently coded by two qualitative 
researchers, with the coding discussed and any discrep-
ancies resolved, to establish a coding frame that can be 
applied to other transcripts. Descriptive accounts will 
summarise key challenges to recruitment. Anonymised 
findings will be documented and synthesised for presen-
tation to the RCT CI.
Access to study data: Access to the study data will be 
limited to authorised personnel. Data will be collected 
and retained in accordance with the UK Data Protection 
Act 1998. An anonymised dataset will be held for future 
research as per the National Institute for Health Research 
contractual arrangements.
Ethics
The trial is managed by the Clinical Trials and Evalua-
tion Unit Bristol (Bristol Trials Centre) and sponsored 
by Royal Brompton & Harefield NHS Foundation Trust. 
Participants have the right to withdraw at any time and 
if they do withdraw, data collected up until the time of 
withdrawal will be included in the analyses, unless the 
participant expresses a wish for their data to be destroyed. 
Withdrawing patients will be asked at this point if they 
can be contacted to complete HRQoL questionnaires for 
an assessment of physical function (primary end point). 
Participants who choose to withdraw from the study will be 
treated according to their hospitals’ standard procedures.
Changes to the protocol since it was first approved
The number of VATS lobectomies performed for 
surgeons to be eligible to participate in the VIOLET study 
was reduced from >50 to >40 to allow more surgeons to 
participate as there was no evidence to suggest a material 
difference in outcome. Version 5.0 (dated 13/02/2018) 
of the protocol is currently in use.
Trial entry criteria by stage were amended following the 
introduction of the eighth edition of the TNM grading to:
a. Lobectomy or bilobectomy for treatment of known or 
suspected primary lung cancer beyond lobar orifice* 
in TNM8 stage cT1-3 (by size criteria, equivalent to 
TNM7 stage cT1a-2b) or cT3 (by virtue of 2 nodules in 
the same lobe), N0-1 and M0 or
b. Undergoing frozen section biopsy with the intention 
to proceed with lobectomy or bilobectomy if primary 
lung cancer with a peripheral tumour beyond a lobar 
orifice* in TNM8 stage cT1-3 (by size criteria, equiv-
alent to TNM7 stage cT1a-2b) or cT3 (by virtue of 2 
nodules in the same lobe), N0-1 and M0 is confirmed.
*In the case of bilobectomy, the distance for the ‘lobar’ 
orifice is in reference to the bronchus intermedius.
The protocol was amended so that the research nurse 
at the site could obtain questionnaire data during a study 
visit or telephone call, for those participants who do 
not return their questionnaire. The relevant regulatory 
approvals were obtained for amendments to the protocol. 
Relevant parties (eg, investigators, trial participants) were 
informed.
study status
The actual numbers recruited at 18 months were 160 
randomised participants and having received TSC and 
funder approval, phase 2 is ongoing and the study is 
actively recruiting in eight centres. The centres opened 
in phase 2 are Heartlands Hospital in Birmingham, John 
Radcliffe Hospital in Oxford and Castle Hill Hospital in 
Hull.
The full protocol is available from: https://www. jour-
nalslibrary. nihr. ac. uk/ programmes/ hta/ 130403/
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